CN111518627A - Contact lens care solution and preparation method thereof - Google Patents
Contact lens care solution and preparation method thereof Download PDFInfo
- Publication number
- CN111518627A CN111518627A CN202010387156.5A CN202010387156A CN111518627A CN 111518627 A CN111518627 A CN 111518627A CN 202010387156 A CN202010387156 A CN 202010387156A CN 111518627 A CN111518627 A CN 111518627A
- Authority
- CN
- China
- Prior art keywords
- parts
- contact lens
- lens care
- care solution
- ectoin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title abstract description 5
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 claims abstract description 61
- 239000003906 humectant Substances 0.000 claims abstract description 30
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 26
- 230000003204 osmotic effect Effects 0.000 claims abstract description 25
- 239000004094 surface-active agent Substances 0.000 claims abstract description 22
- 239000002738 chelating agent Substances 0.000 claims abstract description 18
- 239000006172 buffering agent Substances 0.000 claims abstract description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 42
- 229920002674 hyaluronan Polymers 0.000 claims description 28
- 229960003160 hyaluronic acid Drugs 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 17
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 15
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 14
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 12
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 12
- -1 ectoin sodium salt Chemical class 0.000 claims description 12
- 229920001983 poloxamer Polymers 0.000 claims description 11
- 229960000502 poloxamer Drugs 0.000 claims description 8
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 8
- 159000000000 sodium salts Chemical class 0.000 claims description 8
- 229920001992 poloxamer 407 Polymers 0.000 claims description 6
- 229940044476 poloxamer 407 Drugs 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 5
- KIIBBJKLKFTNQO-WHFBIAKZSA-N 5-hydroxyectoine Chemical compound CC1=N[C@H](C(O)=O)[C@@H](O)CN1 KIIBBJKLKFTNQO-WHFBIAKZSA-N 0.000 claims description 4
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 claims description 4
- 229920002362 Tetronic® 1304 Polymers 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- 229940073499 decyl glucoside Drugs 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- 229940075582 sorbic acid Drugs 0.000 claims description 4
- 235000010199 sorbic acid Nutrition 0.000 claims description 4
- 239000004334 sorbic acid Substances 0.000 claims description 4
- 150000003751 zinc Chemical class 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 abstract description 10
- 230000001050 lubricating effect Effects 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 230000008961 swelling Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 75
- 230000000052 comparative effect Effects 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 239000011259 mixed solution Substances 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000007788 liquid Substances 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 10
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229940010747 sodium hyaluronate Drugs 0.000 description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 8
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000028006 Corneal injury Diseases 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229960003260 chlorhexidine Drugs 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 239000000882 contact lens solution Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- KIIBBJKLKFTNQO-UHFFFAOYSA-N 5-hydroxy-2-methyl-1,4,5,6-tetrahydropyrimidin-3-ium-6-carboxylate Chemical compound CC1=NCC(O)C(C(O)=O)N1 KIIBBJKLKFTNQO-UHFFFAOYSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 241000206595 Halomonas elongata Species 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/66—Non-ionic compounds
- C11D1/722—Ethers of polyoxyalkylene glycols having mixed oxyalkylene groups; Polyalkoxylated fatty alcohols or polyalkoxylated alkylaryl alcohols with mixed oxyalkylele groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/04—Water-soluble compounds
- C11D3/046—Salts
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/20—Organic compounds containing oxygen
- C11D3/22—Carbohydrates or derivatives thereof
- C11D3/221—Mono, di- or trisaccharides or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/20—Organic compounds containing oxygen
- C11D3/22—Carbohydrates or derivatives thereof
- C11D3/222—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin
- C11D3/227—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin with nitrogen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/26—Organic compounds containing nitrogen
- C11D3/28—Heterocyclic compounds containing nitrogen in the ring
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/26—Organic compounds containing nitrogen
- C11D3/30—Amines; Substituted amines ; Quaternized amines
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/26—Organic compounds containing nitrogen
- C11D3/32—Amides; Substituted amides
- C11D3/323—Amides; Substituted amides urea or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/26—Organic compounds containing nitrogen
- C11D3/33—Amino carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Eyeglasses (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The application discloses a contact lens care solution, which comprises ectoin or an ophthalmologically acceptable ectoin derivative, a surfactant, an antibacterial agent, a humectant, a buffering agent, an osmotic pressure regulator and a chelating agent. The application also provides a preparation method of the contact lens care solution. The application provides a contact lens care solution, uses contact lens care solution can promote contact lens's moisturizing lubricating property, promotes and wears the comfort level to have the repairing action, can eliminate because of wearing phenomenons such as red swelling, inflammation that contact lens arouses for a long time.
Description
Technical Field
The application relates to the technical field of contact lenses, in particular to a contact lens care solution and a preparation method thereof.
Background
With the change of life style and working conditions of people, people have more and more time to use eyes, such as watching computers, watching televisions, playing electronic games and the like for a long time, the contact lenses not only bring great improvement to patients with ametropia, such as myopia, hyperopia, astigmatism and the like from the aspects of appearance and convenience, but also have the advantages of large visual field, less image distortion and the like, and more people select to wear the contact lenses.
Contact lenses are exposed to an environment that is likely to come into contact with microorganisms during wearing or storage, and therefore, they are likely to become a hotbed for microorganisms and to be contaminated. Soft contact lenses are highly hydrophilic, mostly charged, and prone to build up of proteins and lipids during use or storage, which can cause damage to the lens wearer's eyes. Thus, contact lenses cannot be worn continuously for long periods of time and must be removed daily for cleaning and disinfection.
The contact lens care solution has the basic functions of cleaning, disinfecting and deproteinizing contact lenses, and most of the contact lens care solutions on the market at present contain disinfectant components such as chlorhexidine, benzalkonium chloride and the like, and have certain damage to the eyes. In addition, the existing contact lens care solution has insufficient moisturizing function, and the problems of dry eyes, corneal loss, inflammation and the like are easily caused after a user wears the contact lens care solution.
Disclosure of Invention
In view of the above, the present application provides an ectoin-containing contact lens care solution, which can improve the moisturizing and lubricating performance of contact lenses, improve wearing comfort, and has a repairing effect, and can eliminate red swelling, inflammation and other phenomena caused by wearing contact lenses for a long time.
In order to achieve the above objects, according to one aspect of the present application, there is provided a contact lens care solution and a method for preparing the same.
The present application provides the following technical solutions.
1. A contact lens care solution comprising ectoin or an ophthalmologically acceptable derivative of ectoin, a surfactant, an antibacterial agent, a humectant, a buffering agent, an osmotic pressure regulator, and a chelating agent.
2. The contact lens care solution according to item 1, comprising the following contact lens care solutions in 100 parts by weight relative to the total weight:
ectoin or an ophthalmologically acceptable ectoin derivative: 0.01-3.0 parts;
surfactant (b): 0.01-5.0 parts;
antibacterial agents: 0.05-3 parts;
humectant: 0.01-0.5 part;
buffering agent: 0.005-10 parts;
osmotic pressure regulator: 0.01-4.0 parts;
chelating agent: 0.001 to 5.0 portions.
3. The contact lens care solution according to item 1, comprising the following contact lens care solutions in 100 parts by weight relative to the total weight:
ectoin or an ophthalmologically acceptable ectoin derivative: 0.5-2.5 parts;
surfactant (b): 0.5-1.5 parts;
antibacterial agents: 0.1-1 part;
humectant: 0.05-0.15 part;
buffering agent: 0.01-5 parts;
osmotic pressure regulator: 0.05-2 parts;
chelating agent: 0.01-3 parts.
4. The contact lens care solution according to any one of claims 1 to 3, wherein the ophthalmologically acceptable ectoin derivative is one or more selected from the group consisting of hydroxyectoin, ectoin sodium salt and ectoin potassium salt.
5. The contact lens care solution according to any one of claims 1 to 3, wherein the surfactant is one or more selected from poloxamer, decyl glucoside, glyceride, Tetronic1107, Tetronic1304, PEG-40 hydrogenated castor oil, and thiobetaine, preferably poloxamer, and more preferably poloxamer 407.
6. The contact lens care solution according to any one of claims 1 to 3, wherein the antimicrobial agent is one or more selected from the group consisting of dipotassium glycyrrhizinate, polyhexamethylene guanidine, and sorbic acid, and preferably dipotassium glycyrrhizinate.
7. The contact lens care solution according to any one of claims 1 to 3, wherein the humectant is a hyaluronic acid-based substance selected from one or more of hyaluronic acid, a hyaluronate salt, a hyaluronic acid derivative and a hyaluronate salt derivative, preferably one or more of a hyaluronate salt and a hyaluronate salt derivative, and more preferably a hyaluronate salt.
8. The contact lens care solution according to claim 7, wherein the hyaluronic acid salt is one or more selected from a sodium salt, a potassium salt, a calcium salt, a zinc salt, and a magnesium salt of hyaluronic acid, and preferably a sodium salt of hyaluronic acid.
9. The contact lens care solution according to item 7, wherein the hyaluronic acid-based substance has a molecular weight of 0.1 × 106Da-4.0×106Da, preferably 1.3 × 10 molecular weight6Da-1.5×106Da and molecular weight 0.2 × 106Da-0.4×106A combination of Da.
10. The contact lens care solution according to item 9, wherein the molecular weight is 1.3 × 106Da-1.5×106Da and molecular weight 0.2 × 106Da-0.4×106The weight ratio of the hyaluronic acid substances of Da is 1 (0.05-20), preferably 1: 4.
11. the contact lens care solution according to any one of claims 1 to 3, wherein the buffer is one or more selected from borate, phosphate and citrate, preferably borate.
12. The contact lens care solution according to any one of claims 1 to 3, wherein the osmotic pressure regulator is one or more selected from the group consisting of sodium chloride, potassium chloride, mannitol and sorbitol, and preferably sodium chloride.
13. The contact lens care solution according to any one of claims 1 to 3, wherein the chelating agent is at least one selected from EDTA, DTPA, EGTA, HEDTA, NTA, and triethanolamine, preferably EDTA-2 Na.
14. The contact lens care solution according to any one of claims 1 to 3, wherein the care solution further comprises hydrochloric acid or sodium hydroxide, and the pH of the care solution is adjusted to 6.0 to 8.0, preferably 7.0 to 7.5 by hydrochloric acid and sodium hydroxide; the osmotic pressure of the care solution is 260-340mOsm/L, and is preferably 290 mOsm/L.
15. A method for preparing a contact lens care solution, comprising the steps of:
adding water for injection into a dissolving tank;
adding the humectant into a dissolving tank while stirring, and stirring until the humectant is completely dissolved;
uniformly mixing the ectoin or an ophthalmologically acceptable ectoin derivative, a surfactant, an antibacterial agent, a humectant, a buffering agent, an osmotic pressure regulator and a chelating agent, slowly adding the mixture into the dissolving tank, and stirring to completely dissolve the mixture to obtain a first mixed solution;
finely adjusting the pH value of the mixed solution I by using hydrochloric acid and sodium hydroxide to obtain a mixed solution II;
and filtering the mixed solution II in the dissolving tank to obtain the liquid which is the contact lens care solution.
16. The method according to claim 15, wherein the water in the dissolving tank is heated to 80-85 ℃ before the humectant is added, and after the humectant is added, the temperature is maintained at 80-85 ℃, the water is stirred for 2-4h until the humectant is completely dissolved, and then the temperature is reduced to 35-40 ℃.
17. The method for preparing a contact lens care solution according to claim 15, wherein the pH of the first mixed solution is adjusted to 6.0 to 8.0, preferably 7.0 to 7.5 by the hydrochloric acid or the sodium hydroxide; the osmotic pressure of the contact lens care solution is 260-340mOsm/L, and preferably 290 mOsm/L.
18. The method according to claim 15, wherein the second mixed solution is filtered through a 5-10 μm filter element, and the resulting liquid is a contact lens solution.
19. The method according to item 15, comprising the following steps of 100 parts by weight of the contact lens solution, based on the total weight:
ectoin or an ophthalmologically acceptable ectoin derivative: 0.01-3.0 parts;
surfactant (b): 0.01-5.0 parts;
antibacterial agents: 0.05-3 parts;
humectant: 0.01-0.5 part;
buffering agent: 0.005-10 parts;
osmotic pressure regulator: 0.01-4.0 parts;
chelating agent: 0.001 to 5.0 portions.
20. The method according to item 15, comprising the following steps of 100 parts by weight of the contact lens solution, based on the total weight:
ectoin or an ophthalmologically acceptable ectoin derivative: 0.5-2.5 parts;
surfactant (b): 0.5-1.5 parts;
antibacterial agents: 0.1-1 part;
humectant: 0.05-0.15 part;
buffering agent: 0.01-5 parts;
osmotic pressure regulator: 0.05-2 parts;
chelating agent: 0.01-3 parts.
21. The method according to any one of claims 15 to 20, wherein the ophthalmologically acceptable ectoin derivative is one or more selected from the group consisting of hydroxyectoin, ectoin sodium salt and ectoin potassium salt.
22. The method of any one of claims 15 to 20, wherein the surfactant is one or more selected from poloxamer, decyl glucoside, glyceride, Tetronic1107, Tetronic1304, PEG-40 hydrogenated castor oil, and thiobetaine, preferably poloxamer, and more preferably poloxamer 407.
23. The method for producing a contact lens care solution according to any one of claims 15 to 20, wherein the antimicrobial agent is one or two or three selected from the group consisting of dipotassium glycyrrhizinate, polyhexamethylene guanidine and sorbic acid, and preferably dipotassium glycyrrhizinate.
24. The method of producing a contact lens care solution according to any one of claims 15 to 20, wherein the humectant is a hyaluronic acid-based substance selected from one or more of hyaluronic acid, a hyaluronic acid salt, a hyaluronic acid derivative and a hyaluronic acid salt derivative, preferably one or more of a hyaluronic acid salt and a hyaluronic acid salt derivative, and more preferably a hyaluronic acid salt.
25. The method according to claim 24, wherein the hyaluronic acid salt is one or more selected from a sodium salt, a potassium salt, a calcium salt, a zinc salt, and a magnesium salt of hyaluronic acid, and preferably a sodium salt of hyaluronic acid.
26. The method according to claim 24, wherein the hyaluronic acid-based substance has a molecular weight of 0.1 × 106Da-4.0×106Da, preferably 1.3 × 10 molecular weight6Da-1.5×106Da and molecular weight 0.2 × 106Da-0.4×106A combination of Da.
27. The method according to item 26, wherein the molecular weight of the solution is 1.3 × 106Da-1.5×106Da and molecular weight 0.2 × 106Da-0.4×106Transparency of DaThe weight ratio of the mass acid substances is 1: (0.05-20), preferably 1: 4.
28. the method of producing a contact lens care solution according to any one of claims 15 to 20, wherein the buffer is one or more selected from borate, phosphate and citrate, preferably borate.
29. The method for producing a contact lens care solution according to any one of claims 15 to 20, wherein the osmotic pressure adjusting agent is one or more selected from the group consisting of sodium chloride, potassium chloride, mannitol and sorbitol, and preferably sodium chloride.
30. The method for preparing a contact lens care solution according to any one of claims 15 to 20, wherein the chelating agent is at least one selected from EDTA, DTPA, EGTA, HEDTA, NTA, triethanolamine, preferably EDTA-2 Na.
The contact lens care solution provided by the application has safe and non-irritant components, the antibacterial effect can be further enhanced due to the combined use of the ectoine with the antibacterial agent at a certain concentration, the antibacterial effect of the used antibacterial agent is not lower than that of the conventional antibacterial agent chlorhexidine and benzalkonium chloride, and the contact lens care solution is safer, non-toxic and non-irritant to use and cannot cause damage to eyes.
The application provides a contact lens care solution, the hyaluronic acid class material with certain mass fraction and molecular weight is the humectant, use with the many reasons for cooperation of the YKE of certain concentration, demonstrate excellent lubricating property of moisturizing, through the contrast, the care solution moisturizing that the application provided keeps wet and the lubricating property is obviously superior to the care solution that only contains hyaluronic acid or many reasons for YKE class material, can obviously reduce the wearing and tearing between contact lens and the cornea, avoid wearing the contact lens for a long time and arouse that the glasses are dry and astringent and uncomfortable, promote and wear the comfort level.
The contact lens care solution provided by the application also has a repairing effect, can protect corneal epithelial cells and accelerate cell regeneration, and eliminates the phenomena of inflammation, red swelling, red blood streak and the like which are generated.
Detailed Description
The following description of the exemplary embodiments of the present application, including various details of the embodiments of the present application to assist in understanding, should be taken as exemplary only. Accordingly, those of ordinary skill in the art will recognize that various changes and modifications of the embodiments described herein can be made without departing from the scope and spirit of the present application. Also, descriptions of well-known functions and constructions are omitted in the following description for clarity and conciseness.
The application provides a contact lens care solution, which comprises ectoin or an ophthalmologically acceptable ectoin derivative, a surfactant, an antibacterial agent, a humectant, a buffering agent, an osmotic pressure regulator and a chelating agent.
Ectoin (2-methyl-1, 4,5, 6-tetrahydropyrimidine-4-carboxylic acid, Ectoin) is derived from halophilic bacteria (Halomonas Elongata) which is the most widely distributed compatible solute in the bacterial kingdom and is compatible with metabolism in cells, does not influence the biomacromolecule function or physiological function of the cells, and is an important osmotic pressure compensation solute. The intensive charge distribution on the surface of the ectoine enables the ectoine to further strengthen the hydrogen bond effect between water molecules through the electrostatic interaction between the ectoine and the water molecules, reduces the water activity, complexes the water molecules and has the long-acting moisturizing effect. The ectoin can reduce the expression of proinflammatory factors and inflammatory factors, block inflammatory reaction and protect biomolecules and cells.
The surfactant is a substance which has fixed hydrophilic and lipophilic groups, can be directionally arranged on the surface of a solution and can obviously reduce the surface tension. It is a large class of organic compounds, and the properties of the compounds are very characteristic, and the compounds are very flexible and wide in application and have great practical value and theoretical significance. Surfactants are used in this application to clean stains from contact lenses.
The antibacterial agent is a medicament for preventing and treating plant diseases caused by various pathogenic microorganisms. The antimicrobial agents described herein are used to inhibit, kill microorganisms on contact lenses.
The moisturizer is a hydrophilic skin moisturizing substance, has the capacity of combining water in a lower humidity range and replenishes water for the skin, can maintain the skin in a balanced state with higher than normal water content by controlling the exchange of water between a product and ambient air, plays a role in relieving the dryness of the skin, and can obviously reduce the abrasion between a contact lens and a cornea, avoid the dryness and discomfort of eyes caused by wearing the contact lens for a long time and improve the wearing comfort level.
Buffers in chemical engineering are often called acid-base stabilizers, and are generally salts, such as salts of strong acids, weak bases or weak acids, strong bases, which gradually release the acid or base from the salt during reaction or preservation to maintain a stable acid-base value. The buffer functions in the present application to adjust the pH of the contact lens care solution.
In the present application, the contact lens care solution comprises the following contact lens care solutions in 100 parts by weight relative to the total weight:
ectoin or an ophthalmologically acceptable ectoin derivative: 0.01-3.0 parts;
surfactant (b): 0.01-5.0 parts;
antibacterial agents: 0.05-3 parts;
humectant: 0.01-0.5 part;
buffering agent: 0.005-10 parts;
osmotic pressure regulator: 0.01-4.0 parts;
chelating agent: 0.001 to 5.0 portions.
In the present application, further the contact lens care solution comprises the following contact lens care solutions in 100 parts by weight relative to the total weight:
ectoin or an ophthalmologically acceptable ectoin derivative: 0.5-2.5 parts;
surfactant (b): 0.5-1.5 parts;
antibacterial agents: 0.1-1 part;
humectant: 0.05-0.15 part;
buffering agent: 0.01-5 parts;
osmotic pressure regulator: 0.05-2 parts;
chelating agent: 0.01-3 parts.
In the present application, the content of the ectoin or the ophthalmologically acceptable ectoin derivative may be 0.01 part, 0.02 part, 0.03 part, 0.04 part, 0.05 part, 0.06 part, 0.07 part, 0.08 part, 0.09 part, 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part, 1.1 part, 1.2 part, 1.3 part, 1.4 part, 1.5 part, 1.6 part, 1.7 part, 1.8 part, 1.9 part, 2 part, 2.1 part, 2.2 part, 2.3 part, 2.4 part, 2.5 part, 2.6 part, 2.7 part, 2.8 part, 2.9 part, 3 part.
In the present application, the content of the surfactant may be 0.01 parts, 0.02 parts, 0.03 parts, 0.04 parts, 0.05 parts, 0.06 parts, 0.07 parts, 0.08 parts, 0.09 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 part, 1.1 parts, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2 parts, 2.1 parts, 2.2 parts, 2.3 parts, 2.4 parts, 2.5 parts, 2.6 parts, 2.7 parts, 2.8 parts, 2.9 parts, 3 parts, 3.1 parts, 3.2 parts, 3.3 parts, 4.4 parts, 3.5 parts, 4.6 parts, 4.7 parts, 4.8 parts, 4.9 parts, 3.5 parts, 4.4 parts, 4.6 parts, 4.7 parts, 4 parts, 4.4 parts, 4.5 parts, 4.6 parts, 4 parts, 4.7 parts, 4.8 parts, 4 parts, 4.5 parts, 4 parts, 4.6 parts, 4 parts, 4.8 parts, 4 parts, 3.6 parts, 4.8.
In the present application, the antibacterial agent may be 0.05 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 part, 1.1 parts, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2 parts, 2.1 parts, 2.2 parts, 2.3 parts, 2.4 parts, 2.5 parts, 2.6 parts, 2.7 parts, 2.8 parts, 2.9 parts, 3 parts.
In the present application, the humectant may be 0.01 parts, 0.02 parts, 0.03 parts, 0.04 parts, 0.05 parts, 0.06 parts, 0.07 parts, 0.08 parts, 0.09 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts.
In the present application, the buffer is 0.005 parts, 0.01 parts, 0.02 parts, 0.03 parts, 0.04 parts, 0.05 parts, 0.06 parts, 0.07 parts, 0.08 parts, 0.09 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 part, 1.1 parts, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2 parts, 2.1 parts, 2.2 parts, 2.3 parts, 2.4 parts, 2.5 parts, 2.6 parts, 2.7 parts, 2.8 parts, 2.9 parts, 3 parts, 3.1 parts, 3.2 parts, 3.3 parts, 3.4 parts, 3.5 parts, 4.5 parts, 4.6 parts, 4.7 parts, 6 parts, 2.8 parts, 3.9 parts, 3 parts, 3.1 parts, 3.2.2.3 parts, 3.3.3, 3.3, 3.3.5 parts, 4.5 parts, 4.6, 6, 6.6, 4.6 parts, 6, 4.6, 6, 4.5.6, 6, 4.6, 6, 4.5, 6, 4.6, 6, 4.5, 6, 4.6, 6, 4.6, 6, 4.5, 4, 4., 7.3 parts, 7.4 parts, 7.5 parts, 7.6 parts, 7.7 parts, 7.8 parts, 7.9 parts, 8 parts, 8.1 parts, 8.2 parts, 8.3 parts, 8.4 parts, 8.5 parts, 8.6 parts, 8.7 parts, 8.8 parts, 8.9 parts, 9 parts, 9.1 parts, 9.2 parts, 9.3 parts, 9.4 parts, 9.5 parts, 9.6 parts, 9.7 parts, 9.8 parts, 9.9 parts, 10 parts.
In the present application, the osmotic pressure regulator: 0.01 part, 0.02 part, 0.03 part, 0.04 part, 0.05 part, 0.06 part, 0.07 part, 0.08 part, 0.09 part, 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part, 1.1 part, 1.2 part, 1.3 part, 1.4 part, 1.5 part, 1.6 part, 1.7 part, 1.8 part, 1.9 part, 2 parts, 2.1 part, 2.2 part, 2.3 part, 2.4 part, 2.5 part, 2.6 part, 2.7 part, 2.8 part, 2.9 part, 3 part, 3.1 part, 3.2 part, 3.3 part, 3.4 part, 3.5 part, 3.6 part, 3.7 part, 3.8 part, 3.9 part, 3.1 part, 3.2 part, 3.3.3.3.3 part, 3.4 part, 3.5 part, 3.6 part, 3.8 part, 3.9.
In the present application, the chelating agent may be 0.001 parts, 0.005 parts, 0.01 parts, 0.02 parts, 0.03 parts, 0.04 parts, 0.05 parts, 0.06 parts, 0.07 parts, 0.08 parts, 0.09 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 part, 1.1 parts, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2 parts, 2.1 parts, 2.2 parts, 2.3 parts, 2.4 parts, 2.5 parts, 2.6 parts, 2.7 parts, 2.8 parts, 2.9 parts, 3 parts, 3.1 parts, 3.2 parts, 3.3.3 parts, 4 parts, 4.5 parts, 4.6 parts, 4.7 parts, 4.8 parts, 3.9 parts, 3.1 parts, 3.3.3.4 parts, 4.4, 4.5 parts, 4.6 parts, 4, 4.7 parts, 4, 3.6, 4.6, 3.8 parts, 3.9, 3.4.9, 3.4, 3.6, 3.
In the present application, ectoin is 2-methyl-1, 4,5, 6-tetrahydropyrimidine-4-carboxylic acid, and the ophthalmologically acceptable ectoin derivative is one or more selected from hydroxyectoin (1,4,5, 6-tetrahydro-2-methyl-5-hydroxy-4-pyrimidinecarboxylic acid), ectoin sodium salt, and ectoin potassium salt.
In the present application, the surfactant is selected from one or more of poloxamer, decyl glucoside, glyceride, Tetronic1107, Tetronic1304, PEG-40 hydrogenated castor oil, and thiobetaine, preferably poloxamer, more preferably poloxamer 407.
Poloxamers (poloxamers) are polyoxyethylene polyoxypropylene ether block copolymers available under the trade name Pluronic. The surfactant is a novel macromolecular nonionic surfactant.
In the present application, the antibacterial agent is selected from one or more of dipotassium glycyrrhizinate, polyhexamethylene guanidine, and sorbic acid, and is preferably dipotassium glycyrrhizinate.
Dipotassium glycyrrhizinate is white or white-like fine powder, has the purity of 98 percent, has special sweet taste, good water solubility and pure mouthfeel. The dipotassium glycyrrhizinate has multiple effects of bacteriostasis, inflammation diminishing, detoxification, anti-allergy, deodorization and the like. Has wide application in the industries of medicine, cosmetics, daily chemicals, food and the like.
In the present application, the moisturizer is a hyaluronic acid-based substance, and is selected from one or more of hyaluronic acid, a hyaluronate salt, a hyaluronic acid derivative, and a hyaluronate salt derivative, preferably one or more of a hyaluronate salt and a hyaluronate salt derivative, and more preferably a hyaluronate salt.
In the present application, the hyaluronic acid salt is selected from one or more of sodium salt, potassium salt, calcium salt, zinc salt, or magnesium salt of hyaluronic acid, and preferably is sodium salt of hyaluronic acid.
The sodium hyaluronate is a natural high molecular compound, has strong hydrophilic capacity and lubricating capacity, and has the advantages of stabilizing tear film, preventing keratoconjunctival dryness, relieving eye tissue friction, relieving xerophthalmia and the like.
In the present application, the molecular weight of the hyaluronic acid-like substance is 0.1 × 106Da-4.0×106Da, preferably 1.3 × 10 molecular weight6Da-1.5×106Da and molecular weight 0.2 × 106Da-0.4×106A combination of Da.
The hyaluronic acid-like substance may be 0.1 × 10 molecular weight6Da、0.2×106Da、0.3×
106Da、0.4×106Da、0.5×106Da、0.6×106Da、0.7×106Da、0.8×106Da、0.9×106Da、1×106Da、1.1×106Da、1.2×106Da、1.3×106Da、1.4×106Da、1.5×106Da、1.6×106Da、1.7×106Da、1.8×106Da、1.9×106Da、2×106Da、2.1×106Da、2.2×106Da、2.3×106Da、2.4×106Da、2.5×106Da、2.6×106Da、2.7×106Da、2.8×106Da、2.9×106Da、3×106Da、3.1×106Da、3.2×106Da、3.3×106Da、3.4×106Da、3.5×106Da、3.6×106Da、3.7×106Da、3.8×106Da、3.9×106Da、4×106One or more of Da.
In the present application, the molecular weight is 1.3 × 106Da-1.5×106Da and molecular weight 0.2 × 106Da-0.4×106The weight ratio of the hyaluronic acid substances of Da is 1 (0.05-20), preferably 1: 4.
the molecular weight is 1.3 × 106Da-1.5×106Da and molecular weight 0.2 × 106Da-0.4×106The weight ratio of the hyaluronic acid-like substance of Da may be 1:0.05, 1: 0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1: 20.
In the present application, the buffer is selected from one or more of borate, phosphate, citrate, preferably borate.
In the present application, the osmotic pressure regulator is one or more selected from sodium chloride, potassium chloride, mannitol, and sorbitol, and preferably sodium chloride.
In the present application, the chelating agent is selected from at least one of EDTA, DTPA, EGTA, HEDTA, NTA, triethanolamine, preferably EDTA-2 Na.
In the application, the nursing liquid also comprises hydrochloric acid or sodium hydroxide, and the pH value of the nursing liquid is adjusted to be 6.0-8.0, preferably 7.0-7.5 by the hydrochloric acid or the sodium hydroxide; the osmotic pressure of the care solution is 260-340mOsm/L, and is preferably 290 mOsm/L.
The application also provides a preparation method of the contact lens care solution, which comprises the following steps:
the method comprises the following steps: adding water for injection into a dissolving tank;
step two: adding the humectant into a dissolving tank while stirring, and stirring until the humectant is completely dissolved;
step three: uniformly mixing the ectoin or an ophthalmologically acceptable ectoin derivative, a surfactant, an antibacterial agent, a humectant, a buffering agent, an osmotic pressure regulator and a chelating agent, slowly adding the mixture into the dissolving tank, and stirring to completely dissolve the mixture to obtain a first mixed solution;
step four: adjusting the pH value of the mixed solution I by adopting hydrochloric acid or sodium hydroxide to obtain a mixed solution II;
step five: and filtering the mixed solution II in the dissolving tank to obtain the liquid which is the contact lens care solution.
In the application, the water in the dissolving tank is heated to 80-85 ℃ before the humectant is added, the temperature is kept at 80-85 ℃ after the humectant is added, the water is stirred for 2-4 hours until the humectant is completely dissolved, and then the temperature is reduced to 35-40 ℃.
In the present application, the pH of the first mixed solution is finely adjusted by the hydrochloric acid or sodium hydroxide to be in the range of 6.0 to 8.0, preferably 7.0 to 7.5; the osmotic pressure of the mixed solution I is adjusted to be 260-340mOsm/L, preferably 290mOsm/L by the osmotic pressure regulator.
In the present application, the buffer can substantially adjust the pH of the first mixed solution, and the pH of the first mixed solution can be further fine-tuned by hydrochloric acid or sodium hydroxide to ensure the quality of the care solution.
In the application, the second mixed solution is filtered by a filter element with the diameter of 5-10 μm, and the liquid obtained after filtering is the contact lens care solution.
The application contact lens care solution, good antibacterial has good inhibitory action, especially has good inhibitory action to escherichia coli, staphylococcus aureus, pseudomonas aeruginosa and candida albicans, moreover the good lubricating property that has of care solution, in addition the care solution not only can make the contact lens who soaks wear comfortable, free from foreign body sensation, can improve conjunctivitis moreover, protects corneal epithelial cell and accelerates cell regeneration, eliminates phenomenons such as inflammation, red swelling, red blood silk that have produced.
Examples
The experimental methods used in the following examples are all conventional methods, unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
The ectoin and hyaluronic acid were purchased from Huaxi biological corporation.
Example 1
Adding water for injection into dissolving tank, and mixing with molecular weight of 1.3 × 106Da and 0.3 × 106Da sodium hyaluronate (1.3 × 106Da and 0.3 × 106The mass ratio of Da is 1:4) adding the mixture into a dissolving tank while stirring, and stirring until the mixture is completely dissolved; uniformly mixing 0.01g of ectoin, 0.01g of poloxamer 407, 0.05g of dipotassium glycyrrhizinate, 0.005g of borate buffer agent, 0.01g of sodium chloride and 0.001g of EDTA-2Na, slowly adding into the dissolving tank, and stirring to completely dissolve to obtain a first mixed solution; adjusting the pH value of the mixed solution I to 7.2 by using hydrochloric acid to obtain a mixed solution II; and filtering the mixed solution II in the dissolving tank to obtain a liquid which is a contact lens care solution, wherein the osmotic pressure of the contact lens care solution is 290mOsm/L, and the specific parameters are shown in Table 1.
Examples 2 to 9 and comparative examples 1 to 2 were different from example 1 in the content of ectoin, poloxamer 407, dipotassium glycyrrhizinate, EDTA-2Na, borate buffer, sodium chloride, and the molecular weight and content of sodium hyaluronate, and the specific parameters were as shown in table 1.
Example 10 differs from example 4 in that only one molecular weight of sodium hyaluronate was used in example 10, and the specific parameters are shown in table 1.
Example 11 differs from example 4 in the content ratio of the two types of sodium hyaluronate with molecular weight in example 10, and the specific parameters are shown in table 1.
Examples 12-13 differ from example 4 in that only one molecular weight of sodium hyaluronate was used in example 10 and the amount of sodium hyaluronate was different from that in example 4, with the specific parameters shown in table 1.
Comparative example 3 differs from example 4 in that comparative example 3 has no added antimicrobial agent and the specific parameters are shown in table 1.
Comparative example 4 differs from example 4 in that comparative example 4 has no ectoin added and the specific parameters are shown in table 1.
Comparative example 5 differs from example 4 in that comparative example 5 does not have a humectant added and the specific parameters are shown in table 1.
Comparative example 6 differs from example 4 in that the antibacterial agent in comparative example 6 is chlorhexidine, with specific parameters as shown in table 1.
Comparative example 7 differs from example 4 in that the antibacterial agent in comparative example 7 is benzalkonium bromide, and the specific parameters are shown in table 1.
Comparative example 8 is a commercial Haichang contact lens care solution.
Table 1 is a comparative table of raw material compositions of examples and comparative examples
Test examples
1. Bacteriostatic effect
The method disclosed in GB19192-2003 sanitary requirements for contact lens care solutions is adopted to detect the bacteriostatic effect of each example and comparative example on escherichia coli, staphylococcus aureus, pseudomonas aeruginosa and candida albicans, and the specific operation steps are as follows:
testing the microorganisms:
(1) bacteria: escherichia coli (ATCC8739 or 8099), Staphylococcus aureus (ATCC6538), Pseudomonas aeruginosa (ATCC9027)
(2) Yeast: candida albicans (ATCC10231) simulated field trials:
(1) respectively placing test lenses (four low-water-content nonionic types and four high-water-content ionic types in each group) and positive control lenses (two lenses) in a sterilized culture dish, inoculating 0.02mL of test bacterial liquid on the lenses, and absorbing for 5-10 min at 20-25 ℃;
(2) cleaning the test lenses with contact lens care solutions (the contact lens care solutions described in examples 1-13 and comparative examples 1-8), respectively moving the lenses into a 5.0mL neutralizing reagent tube by an aseptic operation method immediately after cleaning, shaking and calculating the number of viable bacteria;
(3) the positive control lens was transferred into a 5.0ml PBS tube by aseptic technique, shaken and the viable count was calculated.
(4) The clearance of each bacterium on the lens was calculated:
the bacteria clearance rate is more than or equal to 99.90 percent and the saccharomycetes clearance rate is more than or equal to 90.00 percent, and the test results are shown in Table 2.
Table 2 shows the bacteriostatic effects of the contact lens care solutions of the examples and comparative examples
And (3) knotting: as can be seen from the above table, the contact lens care solutions prepared in examples 1 to 13 of the present application all have good antibacterial properties, and it can be seen from examples 1 and comparative examples 1 to 2 that the combination of low dose of ectoin and antibacterial agent also has good antibacterial effect, while the combination of ectoin and antibacterial agent lower than a certain proportion has poor antibacterial effect; it can be seen from example 4 and comparative examples 3-4 that the single use of a certain dose of ectoin or antibacterial agent has unsatisfactory bacteriostatic effect, and that the same dose of ectoin and antibacterial agent have good bacteriostatic effect when combined.
2. Evaluation of lubricity
With reference to GB3142-2019 "four-ball method for testing the bearing capacity of lubricants", a four-ball friction wear tester is adopted to evaluate the friction coefficients of the examples and the comparative examples, and the experimental conditions are as follows: the rotation speed is 1450r/min, the temperature is 37 ℃, the test time is 30min, and the diameter of the used ceramic ball is 12.7 mm. The smaller the coefficient of friction, the better the lubricity and the test results are shown in Table 3.
Table 3 shows the lubricating properties of the contact lens care solutions according to the examples and comparative examples
| Coefficient of friction | |
| Example 1 | 0.167 |
| Example 2 | 0.147 |
| Example 3 | 0.068 |
| Example 4 | 0.074 |
| Example 5 | 0.084 |
| Example 6 | 0.072 |
| Example 7 | 0.102 |
| Example 8 | 0.114 |
| Example 9 | 0.091 |
| Example 10 | 0.093 |
| Example 11 | 0.125 |
| Example 12 | 0.166 |
| Example 13 | 0.148 |
| Comparative example 1 | 0.199 |
| Comparative example 2 | 0.223 |
| Comparative example 3 | 0.078 |
| Comparative example 4 | 0.165 |
| Comparative example 5 | 0.244 |
| Comparative example 6 | 0.092 |
| Comparative example 7 | 0.089 |
| Comparative example 8 | 0.159 |
And (3) knotting: as can be seen from the above table, the friction coefficient of the contact lens care solution described in the present application is small, and it can be seen from example 4 and comparative examples 4 and 5 that a certain amount of ectoin added in combination with hyaluronic acid can reduce the friction coefficient of the contact lens lubricating solution and improve the lubricating performance of the product, the friction coefficient of comparative example 5 is not added with hyaluronic acid to the maximum, and the friction coefficient of comparative example 4 is also significantly higher than that of example 4 without adding ectoin. Therefore, the lubrication effect of the sodium hyaluronate can be improved by adding the ectoin with a certain concentration.
3. Evaluation of wearing comfort and moisture retention
The contact lenses soaked in the contact lenses of the example 1 and the example 4 and the comparative examples 1 to 8 are selected to carry out wearing tests, the test objects are respectively 20 adults without eye diseases and with more than one contact lens wearing history, the average age is 30 to 35 years, the wearing time is 2 hours each time, the contact lenses soaked in the different examples or the comparative examples can be worn on two eyes simultaneously, and the interval of the two wearing times of the same person is not less than 2 hours. After completion of the test, the subjects were recorded for comfort and moisture retention as described in table 4.
Table 4 shows the wearing comfort and moisture retention of the contact lens care solutions according to the examples and comparative examples
And (3) knotting: as can be known from the table above, this application contact lens wear comfortablely, the moisturizing is better moreover, embodiment 4 feels comfortable and the number of people who moisturizes obviously is more than embodiment 1 and comparative example, and the contact lens care solution that adds sodium hyaluronate can promote contact lens and wear travelling comfort and moisturizing, adds the ectoine of certain concentration after, wears travelling comfort and moisturizing and further promotes, and it is uncomfortable to add the contact lens care solution that contains chlorhexidine, little child cleaner bacteriostat and wear.
4. Repair performance
4.1 test for ameliorating conjunctival inflammation
The contact lenses soaked in the contact lenses of the examples 1 and 4 and the comparative examples 1 to 5 and 8 were selected for wearing tests, and the test subjects were 40 adults with a mean age of 30 to 35 who had a beautiful pupil contact lens for more than 8 hours per day, a computer and a mobile phone for more than 10 hours per day, had redness and swelling of eyes, had keratitis, and were divided into 8 groups of 5 persons, and the contact lenses soaked in the contact lenses of the examples 1 and 4 and the comparative examples 1 to 5 and the comparative example 8 were worn, and the wearing effect was observed, and the result is shown in table 5.
Table 5 shows the parameters of the restoration performance of the contact lens care solutions according to the examples and comparative examples
And (3) knotting: after wearing the contact lenses soaked in the liquid of example 1 for 20 days, the symptoms are reduced; when the contact lens soaked in the liquid crystal gel is worn, the symptoms of keratitis can be relieved after the contact lens is continuously worn for 10 days, and the symptoms can be cured after the contact lens is continuously worn for 20 days, which shows that the nursing liquid containing a certain amount of addition of the ectoin and the hyaluronic acid has the effect of improving the symptoms of the conjunctivitis.
4.2 corneal injury repair test
The repair degree of corneal injury is judged by measuring the release amount of Lactate Dehydrogenase (LDH) in tears, the LDH release amount is increased, the corneal injury is shown, the LDH release amount is reduced, and the corneal injury is repaired.
Healthy New Zealand white Rabbit 30, each half of male and female, a body weight of 1.8-2.5 kg, and an average of 6 groups, wherein the cornea is irradiated with ultraviolet (UV-B) for 10 minutes (750-2). Each group was treated with the treatment solution prepared in examples 1 and 4 and comparative examples 1, 2, 4 and 5, respectively, 2 drops each time in the right eye 4 times a day for 5 consecutive days without treatment in the left eye.
LDH release was measured for each group before irradiation, after irradiation, 1 day after irradiation, 3 days after irradiation, and 5 days after irradiation, respectively, and the average value was taken for each group.
LDH measurement method: after local instillation and infiltration with 250. mu.l of physiological saline for 1 minute, 50. mu.l of the sample was used to measure the LDH release by a fully automatic biochemical analyzer (Hitachi 7600-020), and the results are shown in Table 6.
Table 6 shows the parameters (unit: IU/L) for repairing corneal damage of the contact lens solutions of examples and comparative examples
And (3) knotting: after ultraviolet irradiation, the LDH release amount shows an ascending trend, which indicates that the rabbit cornea is damaged by ultraviolet rays, the LDH release amount of the right eye after 5 days of irradiation is obviously lower than that of the left eye, the LDH release amount of the right eye of the embodiment 1 and the embodiment 4 is obviously lower than that of the comparative example, and indicates that the nursing liquid compounded by the ectoine and the hyaluronic acid can accelerate the cornea damage repair.
While embodiments of the present application have been described above in connection with specific embodiments thereof, the present application is not limited to the above-described embodiments and fields of application, which are intended to be illustrative, instructive, and not restrictive. Those skilled in the art, having the benefit of this disclosure, may effect numerous modifications thereto and changes may be made without departing from the scope of the invention as defined by the appended claims.
Claims (10)
1. A contact lens care solution comprising ectoin or an ophthalmologically acceptable derivative of ectoin, a surfactant, an antibacterial agent, a humectant, a buffering agent, an osmotic pressure regulator, and a chelating agent.
2. The contact lens care solution according to claim 1, comprising the following contact lens care solution in 100 parts by weight relative to the total weight:
ectoin or an ophthalmologically acceptable ectoin derivative: 0.01-3.0 parts;
surfactant (b): 0.01-5.0 parts;
antibacterial agents: 0.05-3 parts;
humectant: 0.01-0.5 part;
buffering agent: 0.005-10 parts;
osmotic pressure regulator: 0.01-4.0 parts;
chelating agent: 0.001 to 5.0 portions.
3. The contact lens care solution according to claim 1, comprising the following contact lens care solution in 100 parts by weight relative to the total weight:
ectoin or an ophthalmologically acceptable ectoin derivative: 0.5-2.5 parts;
surfactant (b): 0.5-1.5 parts;
antibacterial agents: 0.1-1 part;
humectant: 0.05-0.15 part;
buffering agent: 0.01-5 parts;
osmotic pressure regulator: 0.05-2 parts;
chelating agent: 0.01-3 parts.
4. The contact lens care solution according to any one of claims 1 to 3, wherein the ophthalmologically acceptable ectoin derivative is one or more selected from the group consisting of hydroxyectoin, ectoin sodium salt and ectoin potassium salt.
5. A contact lens care solution according to any one of claims 1 to 3, wherein said surfactant is selected from one or more of poloxamer, decyl glucoside, glyceride, Tetronic1107, Tetronic1304, PEG-40 hydrogenated castor oil, thiobetaine, preferably poloxamer, more preferably poloxamer 407.
6. The contact lens care solution according to any one of claims 1 to 3, wherein the antimicrobial agent is one or two or three selected from the group consisting of dipotassium glycyrrhizinate, polyhexamethylene guanidine, and sorbic acid, and preferably is dipotassium glycyrrhizinate.
7. The contact lens care solution according to any one of claims 1 to 3, wherein the humectant is a hyaluronic acid-based substance selected from one or more of hyaluronic acid, a hyaluronate salt, a hyaluronic acid derivative and a hyaluronate salt derivative, preferably one or more of a hyaluronate salt and a hyaluronate salt derivative, and more preferably a hyaluronate salt.
8. The contact lens care solution according to claim 7, wherein the hyaluronic acid salt is selected from one or more of sodium salt, potassium salt, calcium salt, zinc salt or magnesium salt of hyaluronic acid, preferably sodium salt of hyaluronic acid.
9. The contact lens care solution according to claim 7, wherein the hyaluronic acid-based substance has a molecular weight of 0.1 × 106Da-4.0×106Da, preferably 1.3 × 10 molecular weight6Da-1.5×106Da and molecular weight 0.2 × 106Da-0.4×106A combination of Da.
10. The contact lens care solution of claim 9, wherein the molecular weight is 1.3 × 106Da-1.5×106Da and molecular weight 0.2 × 106Da-0.4×106The weight ratio of the hyaluronic acid substances of Da is 1: (0.05-20), preferably 1: 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010387156.5A CN111518627A (en) | 2020-05-09 | 2020-05-09 | Contact lens care solution and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010387156.5A CN111518627A (en) | 2020-05-09 | 2020-05-09 | Contact lens care solution and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111518627A true CN111518627A (en) | 2020-08-11 |
Family
ID=71907690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010387156.5A Pending CN111518627A (en) | 2020-05-09 | 2020-05-09 | Contact lens care solution and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111518627A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114410391A (en) * | 2022-01-26 | 2022-04-29 | 深圳中科欣扬生物科技有限公司 | Contact lens care solution containing antioxidant substances and preparation method thereof |
| CN114588065A (en) * | 2022-03-31 | 2022-06-07 | 深圳中科欣扬生物科技有限公司 | Ophthalmic composition and preparation method and application thereof |
| CN114748611A (en) * | 2022-03-14 | 2022-07-15 | 深圳中科欣扬生物科技有限公司 | Composition with antioxidant, moisturizing and lubricating effects and application thereof |
| WO2022248127A3 (en) * | 2021-05-26 | 2023-01-05 | Bausch + Lomb Ireland Limited | Packaging solutions |
| CN115956574A (en) * | 2022-12-30 | 2023-04-14 | 烟台爱博诺德医用材料有限公司 | Care composition for optical devices |
| CN116024050A (en) * | 2022-12-14 | 2023-04-28 | 江苏视准医疗器械有限公司 | Cornea contact lens preserving fluid composition and preparation method thereof |
| US20230236133A1 (en) * | 2022-01-21 | 2023-07-27 | Sltg Corporation | Drug Capsule Appearance Inspection Device |
| GR1010664B (en) * | 2023-01-30 | 2024-04-04 | Ιουλια Κλεωνος Τσετη | Repeated-use aqueous solution for contcat lenses containing ectoin and herbal blend |
| WO2025026792A1 (en) * | 2023-07-28 | 2025-02-06 | Bausch + Lomb Ireland Limited | Packaging system for storage of an opthalmic device |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1390606A (en) * | 2002-06-20 | 2003-01-15 | 上海卫康光学有限公司 | Composition for treaitng contact lens and its application |
| CN101691478A (en) * | 2009-09-25 | 2010-04-07 | 海昌隐形眼镜有限公司 | Corneal contact lens nursing composition containing mycose and preparation method thereof |
| CN106867704A (en) * | 2017-01-25 | 2017-06-20 | 东南大学 | A kind of contact lens care solution containing the double cleaning systems of sucrose ester |
| CN108324676A (en) * | 2018-04-28 | 2018-07-27 | 广东巴松那生物科技有限公司 | A kind of promotion of compacting, anti-aging face cream and preparation method thereof |
| CN108478459A (en) * | 2018-04-28 | 2018-09-04 | 广东巴松那生物科技有限公司 | Eye essence containing lactobacillus fermentation lysate and preparation method thereof |
| CN108778250A (en) * | 2016-03-07 | 2018-11-09 | 乌尔萨法姆药物有限责任公司 | Ophthalmic composition |
| CN109722347A (en) * | 2019-01-03 | 2019-05-07 | 山东省药学科学院 | A kind of moisturizing lubricating composition containing xanthan gum and application thereof |
| CN109929702A (en) * | 2018-12-26 | 2019-06-25 | 上海卫康光学眼镜有限公司 | A kind of pair of contact lenses have composition and its application of high-efficiency cleaning disinfection |
| CN110028598A (en) * | 2019-04-29 | 2019-07-19 | 扬州中福生物技术有限公司 | A method of optimization hyaluronan molecule amount distribution |
-
2020
- 2020-05-09 CN CN202010387156.5A patent/CN111518627A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1390606A (en) * | 2002-06-20 | 2003-01-15 | 上海卫康光学有限公司 | Composition for treaitng contact lens and its application |
| CN101691478A (en) * | 2009-09-25 | 2010-04-07 | 海昌隐形眼镜有限公司 | Corneal contact lens nursing composition containing mycose and preparation method thereof |
| CN108778250A (en) * | 2016-03-07 | 2018-11-09 | 乌尔萨法姆药物有限责任公司 | Ophthalmic composition |
| CN106867704A (en) * | 2017-01-25 | 2017-06-20 | 东南大学 | A kind of contact lens care solution containing the double cleaning systems of sucrose ester |
| CN108324676A (en) * | 2018-04-28 | 2018-07-27 | 广东巴松那生物科技有限公司 | A kind of promotion of compacting, anti-aging face cream and preparation method thereof |
| CN108478459A (en) * | 2018-04-28 | 2018-09-04 | 广东巴松那生物科技有限公司 | Eye essence containing lactobacillus fermentation lysate and preparation method thereof |
| CN109929702A (en) * | 2018-12-26 | 2019-06-25 | 上海卫康光学眼镜有限公司 | A kind of pair of contact lenses have composition and its application of high-efficiency cleaning disinfection |
| CN109722347A (en) * | 2019-01-03 | 2019-05-07 | 山东省药学科学院 | A kind of moisturizing lubricating composition containing xanthan gum and application thereof |
| CN110028598A (en) * | 2019-04-29 | 2019-07-19 | 扬州中福生物技术有限公司 | A method of optimization hyaluronan molecule amount distribution |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022248127A3 (en) * | 2021-05-26 | 2023-01-05 | Bausch + Lomb Ireland Limited | Packaging solutions |
| US12012238B2 (en) | 2021-05-26 | 2024-06-18 | Bausch + Lomb Ireland Limited | Packaging solutions |
| US20230236133A1 (en) * | 2022-01-21 | 2023-07-27 | Sltg Corporation | Drug Capsule Appearance Inspection Device |
| CN114410391A (en) * | 2022-01-26 | 2022-04-29 | 深圳中科欣扬生物科技有限公司 | Contact lens care solution containing antioxidant substances and preparation method thereof |
| CN114748611A (en) * | 2022-03-14 | 2022-07-15 | 深圳中科欣扬生物科技有限公司 | Composition with antioxidant, moisturizing and lubricating effects and application thereof |
| CN114588065A (en) * | 2022-03-31 | 2022-06-07 | 深圳中科欣扬生物科技有限公司 | Ophthalmic composition and preparation method and application thereof |
| CN116024050A (en) * | 2022-12-14 | 2023-04-28 | 江苏视准医疗器械有限公司 | Cornea contact lens preserving fluid composition and preparation method thereof |
| CN115956574A (en) * | 2022-12-30 | 2023-04-14 | 烟台爱博诺德医用材料有限公司 | Care composition for optical devices |
| GR1010664B (en) * | 2023-01-30 | 2024-04-04 | Ιουλια Κλεωνος Τσετη | Repeated-use aqueous solution for contcat lenses containing ectoin and herbal blend |
| WO2025026792A1 (en) * | 2023-07-28 | 2025-02-06 | Bausch + Lomb Ireland Limited | Packaging system for storage of an opthalmic device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111518627A (en) | Contact lens care solution and preparation method thereof | |
| CN101574537B (en) | Composition for contact lens solution containing peppermint and preparation method thereof | |
| ES2374607T3 (en) | Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid. | |
| CN111991415B (en) | Eye care composition and preparation method and application thereof | |
| EP2046287B1 (en) | Methods and compositions for the treatment and prevention of infections | |
| WO2003086442A2 (en) | Ophthalmic, pharmaceutical and other healthcare preparations with naturally occuring plant compounds, extracts and derivatives | |
| CN1182877C (en) | Composition for treaitng contact lens and its application | |
| CN114588065A (en) | Ophthalmic composition and preparation method and application thereof | |
| CN114410391A (en) | Contact lens care solution containing antioxidant substances and preparation method thereof | |
| Jones et al. | Soft contact lens solutions review part 1: components of modern care regimens | |
| JPH0368503A (en) | Liquid medicine for contact lens | |
| CN114344253B (en) | Deuterium-depleted water contact lens eye-wetting liquid and preparation method thereof | |
| CN115068595A (en) | Anti-radiation composition for eyes and preparation method and application thereof | |
| JP4981181B1 (en) | Contact lens composition | |
| CN109722347B (en) | A kind of moisturizing lubricating composition containing xanthan gum and application thereof | |
| JP2000507200A (en) | Compositions for treating ocular complications associated with hypoxia | |
| CN104136005A (en) | Ophthalmic compositions with alkoxylated natural waxes | |
| CN108853556A (en) | A kind of contact lens,hard care composition and preparation method thereof containing sodium lactate | |
| HU209538B (en) | Set and cleaning composition for treating contactlenses | |
| CN1302765C (en) | Ophthalmic solution containing borneol and usage thereof | |
| CN108310442B (en) | Ophthalmic composition | |
| KR101134340B1 (en) | A eye-drop composition for preventing or treating ocular diseases | |
| TWI854139B (en) | Liquid composition for storing contact lenses | |
| TWI673071B (en) | Ophthalmic composition | |
| TWI846252B (en) | Antibacterial moisturizing contact lens liquid composition and packaging solution made thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200811 |